LCRC is characterized by a PS program, lower malignancy scores linked to LPCAT2+ cells (which inhibit tumor growth and induce ferroptosis), enhanced mucosal healing/protein folding, and tumor cells localized in glycolytic niches interacting with specific immune cells (PLTP+ macrophages, Tregs, LAYN+ CD8+ cells). The gene discussed is LPCAT2; the disease is neoplasm.